within Pharmacolibrary.Drugs.ATC.S;

model S01EE51
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01EE51</td></tr><td>route:</td><td>ocular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Latanoprost and netarsudil is a fixed-dose combination ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Latanoprost is a prostaglandin F2α analogue increasing uveoscleral outflow, while netarsudil is a Rho kinase inhibitor that reduces intraocular pressure by increasing trabecular outflow and decreasing episcleral venous pressure. The combination is approved and marketed under brand names such as Rocklatan or Roclanda.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic parameters have been reported in the literature for the fixed combination of latanoprost and netarsudil (S01EE51) in humans. Individual drug PK data exist but not for the combination product.</p><h4>References</h4><ol><li><p>Sinha, S, et al., &amp; Razeghinejad, R (2020). Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension. <i>Expert opinion on pharmacotherapy</i> 21(1) 39–45. DOI:<a href=\"https://doi.org/10.1080/14656566.2019.1685499\">10.1080/14656566.2019.1685499</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31663782/\">https://pubmed.ncbi.nlm.nih.gov/31663782</a></p></li><li><p>Wang, T, et al., &amp; Jiang, Q (2022). A novel fixed-combination timolol-netarsudil-latanoprost ophthalmic solution for the treatment of glaucoma and ocular hypertension. <i>Asian journal of pharmaceutical sciences</i> 17(6) 938–948. DOI:<a href=\"https://doi.org/10.1016/j.ajps.2022.11.001\">10.1016/j.ajps.2022.11.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36600899/\">https://pubmed.ncbi.nlm.nih.gov/36600899</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01EE51;
